Urinary incontinence arising from several conditions is a common symptom in many women, especially women who had previous vaginal deliveries. Stress urinary incontinence (SUI) is the involuntary loss of urine due to increases in intra-abdominal pressure associated with laughing, lifting, coughing, or other physical activity. SUI may be caused by excessive bladder neck mobility (hypermobility) and/or intrinsic sphincter deficiency (ISD). Bladder neck hypermobility is typically the result of weak periurethral and bladder support tissue which permits the movement of the bladder neck and proximal urethra during times of increased intra-abdominal pressure. ISD is an inherent weakness of the internal urinary sphincter due to scarring or denervation which renders the internal urinary sphincter incompetent. An incompetent urinary sphincter may allow SUI in the absence of bladder neck hypermobility as urine is pushed through the incompetent sphincter with increases in intra-abdominal pressure. Some patients have both bladder neck hypermobility and ISD resulting in extreme SUI. It is important to recognize and understand that SUI is a symptom, not a disease or disorder per se.
A variety of techniques has arisen for treating the symptom of SUI. The techniques primarily involve supporting the urethra in a position where the flow of urine may be controlled by urethral compression during increases in intra-abdominal pressure.
Prior art techniques include a variety of ways to support the urethra. These ways include suturing to musculature or fascia beneath the urethra. Perhaps the most popular recent methods have involved placing a sling or hammock beneath the urethra, and supporting the hammock by anchoring it to fascia or other suitable supports, such as rectus muscle, the pubic bone, Cooper's ligament, or to subcutaneous tissue above the rectus fascia. Prior art slings are depicted in
These prior art techniques have disadvantages in that they are not necessarily stable within the body of the patient. That is, once the sling is placed, it may tend to move, and thus the patient does not receive the benefit of the surgeon's precise placement of the sling for supporting the urethra and gaining the best control over incontinence. Other disadvantages lie in the design of the sling itself. Since at least the central portion of the sling has a constant width, it may be subject to rolling or bunching under the urethra. This may tend to re-form a wide band into a narrow supporting band underneath the urethra, providing less support and possibly cutting into the urethra in extreme cases.
What is needed are improved or alternative slings or hammocks for urethral support. What is needed are slings that will remain where the surgeon places them, and which will gently and reliably support the urethra and potentially other tissue structures, allowing a patient long-term relief from stress urinary incontinence.
One aspect of the invention is a sling for supporting a urethra. The sling comprises a first end portion and a second end portion, and a support portion for supporting the urethra. There is also a first transition segment connecting the first end portion to the support portion, and a second transition segment connecting the second end portion to the support portion. At least one of the transition segments provides a relief.
Another aspect of the invention is a method for supporting a urethra in a patient. The method comprises placing a sling on either side of a urethra, the sling having a support portion, and a first portion and a second end portion connected to the support portion by transition segments, wherein the transition segment defines a relief. The method also comprises creating a path on either side of the urethra, behind a pubic bone of the patient, to an abdomen of the patient. The paths are created by a method selected from the group consisting of a retrograde method and an antegrade method. The method also comprises placing the sling into the paths to anchor the sling to the patient.
Another aspect of the invention is a sling for supporting a urethra of a patient, the sling comprising a support portion, and also having a first portion and a second portion connected to the support portion. The first and second portions have serrations. Another aspect of the invention is a method for supporting a urethra in a patient. The method comprises placing a sling on either side of a urethra, the sling having a support portion, and a first portion and a second portion connected to the support portion, the first and second portions having serrations for anchoring the sling in the patient. The method also comprises creating a path on either side of the urethra, behind a pubic bone of the patient, to an abdomen of the patient. The paths are created by a method selected from the group consisting of a retrograde method and an antegrade method. The method also comprises placing the sling into the paths to anchor the sling to the patient.
Another aspect of the invention is a method for supporting tissue within a body of a patient. The method comprises placing a sling within the body, near the tissue, the sling having a support portion, and a first portion and a second portion, each connected to the support portion by a transition segment, wherein the transition segment defines a relief. The method further comprises creating a path for the first and second portions of the sling, and placing the first and second portions of the sling into the path. The method also comprises anchoring the sling. Another aspect of the invention is a method for supporting tissue within a body of a patient. The method comprises placing a sling within the body, near the tissue, the sling having a support portion, and a first portion and a second portion connected to the support portion, the first and second portions having serrations for anchoring the sling in a patient. The method further comprises creating a path for the first and second portions of the sling, and placing the first and second portions of the sling into the path. The method also comprises anchoring the sling.
There are many ways to practice the present invention, as shown in the following drawings and specification. The embodiments are not meant to limit the invention, but rather to describe and illustrate the many ways that the present invention may be used.
a is a side view of a needle and handle for implanting a sling, and
b is a perspective view of the needle.
The present invention provides slings with adaptations for ameliorating potential causes of pull-out or roll-over of a sling, or a combination of pull-out and roll-over. In some cases, the problem of roll-over may be related to the support portion of the sling, since the primary consideration of this portion in most cases is to provide support for about 1-2 cm of the urethra, spreading the mechanical load and avoiding a stress concentration whereby the sling could damage the urethra. At least one contributor to roll-over forces and roll-over may be the endopelvic fascia, running near the urethra and roughly perpendicular to the sling. The sling may be implanted near the fascia, where the bulk and stiffness of the endopelvic fascia may interfere with a flat, planar installation of the sling by compressing the sling where the fascia pass through the sling. The sling may then be rolled or bunched into a narrow band under the urethra, depriving the urethra of broader, less stressful support.
To facilitate addressing this problem, embodiments of the present invention provide relief near the support portion of the sling. The relief features provide relief for any endopelvic fascia passing transversely to the orientation of the sling when implanted. Narrowing transitions for providing relief are preferably gently radiused so that the sling continues to provide maximum support for the urethra. The transitions are preferably narrower than the adjacent support portion and the left or right side “tail” or supporting portion of the sling. In addition to or as an alternative to narrower portions, relief may be effectively provided by modifying any material in the relief area to render it less resistant to deformation or displacement by surrounding patient tissues. For example, material in the relief area may be windowed, sliced, perforated or otherwise sufficiently weakened or otherwise modified to facilitate the passage of endopelvic fascia without curling or rolling the intermediate portion of the sling device.
Other features may be added to the sling to increase resistance to pull out, for example anchors that provide convoluted surfaces, surfaces that interfere with movement of the sling, thus increasing resistance to pullout or movement. The features or anchors may be protuberances such as barbs, whereby the sling is provided with a plurality of small anchors to prevent movement once the sling is placed into a patient. In addition, or instead of barbs or protuberances, the sling may be provided with serrations on its edges, in order to resist pullout. Other features that may help in anchoring the sling include perforations in the sling, in the support portions or in the transition regions, or both. Some of these anchoring features, especially penetrations or perforations, may also help to encourage the ingrowth of bodily tissue into the sling, thus supporting and stabilizing the sling. These features may help to stabilize the sling within the patient by increasing the surface area that opposes movement within the patient's body.
The features that improve the sling are shown in the figures.
Another embodiment features the serrations discussed above.
Three types of serrations have been tested on a variety of materials to determine resistance to pullout. The three types of serrations are depicted in
Pull-out test specimens were prepared from a variety of sling materials. Tests were conducted by inserting the sling material made of porcine small intestine submucosa (SIS) into cut surfaces of round steaks approximately 1-2 cm thick. The samples were inserted into the steak so that approximately 7 cm of each sample remained to be pulled though the steak by an Instron testing machine. The jaw of the Instron was then connected to the sling and an extension rate of about 100 mm/minute was used to pull the sling against the serrations. Maximum force was recorded as sling failure load (N). Results of the test are shown below in Table 1.
Subsequent testing confirmed that the serrated edges required more force to pull through, and that an 8-layer SIS laminate required at least twice as much force as a 4-layer laminate. Although serrations are clearly effective in resisting pullout, other features may desirably be added to the sling in order to make the sling even more resistant to movement within the patient's body. These features may provide a third-dimensional aspect to the otherwise flat, almost two-dimensional slings. The features may be added during normal processing of the sling material, such as when material is vacuum-processed and pressed, and a form or mold for the material contains voids or perforations for the material to fill, thus adding a desired feature.
In some embodiments, it may be beneficial to encourage the growth of bodily tissue into the sling.
Processes for making multi-layer laminates from a plurality of individual layers of material are disclosed in U.S. Pat. Nos. 5,885,619 and 5,711,969, hereby incorporated by reference in their entirety. Additional teachings as to processing and layering the materials are disclosed in U.S. Pat. Nos. 5,733,337, 5,995,110, 5,993,844, 5,997,575, and 6,206,931, all of which are hereby incorporated by reference in their entirety. These patents teach the harvesting, cleansing, sterilizing and processing the submucosa from a variety of sources, including the alimentary, respiratory, urinary or genital tracts from bovine, ovine and porcine sources. Included in the processing are processes to dehydrate and compress the submucosal tissues. Processes may include vacuum drying, dead-weight pressing or other pressing, lyophilizing, room temperature or heat pressing, perforating, layering, and so on. Slings made from submucosal tissues by these and other processes are meant to be used in the present invention.
The multiple-layer embodiments may contain two laminae to eight or even more laminae of collagenous material. A preferred embodiment is a four-layer or an eight-layer material made from porcine SIS, and vacuum-pressed to bind the layer in the thickness dimension. Any numbers of methods may be used to produce laminates, including the processing described above, mechanical reinforcements in the third (thickness) dimension, and the like.
As mentioned above, the protuberances may be formed during processing of the sling material by forming the material in suitable forms or molds. In one embodiment, the protuberances are in the form of buttons or short cylinders, as shown in
The sling may be used as a part of a kit furnished to a surgeon for inserting the sling into the body of a patient. The other components of such a kit are depicted in
The needle used may be a modified Stamey needle used as a ligature carrier, preferably having a curved portion. The curve is from about 50 degrees to about 75 degrees, shown in
An advantage of a kit which contains the needle and the sling as described above is that the operation for inserting the sling into the body of a female patient may be performed by either an antegrade or a retrograde method. This option is helpful, because some surgeons have only been trained to perform one of the above-mentioned procedures. In addition, due to previous procedures performed on a particular patient, it may be best to perform the operation by one technique rather than the other. As an example, in the antegrade technique the entire needle need not pass through the body of the patient because the sling attaches to the distal end of the needle. Only enough of the needle need pass through so that the surgeon can grasp the sling, or a suture attached to the sling.
An antegrade procedure is depicted in
A retrograde procedure may also be used to place the sling. In the retrograde procedure, a vaginal incision is used, and a rigid catheter guide is deflected to the ipsilateral side just before inserting the needle, in order to minimize the risk of bladder or urethral perforation. The needle or ligature carrier is inserted into a previously developed paraurethral space and advanced slightly laterally, maintaining contact with the back of the pubic bone as much as possible to minimize the risk of vascular injury. The surgeon may remove the handle from the needle and the sling, or a suture attached to the sling, is placed through the aperture in the proximal end of the needle, and one portion of the sling is pulled through the tract or space developed by the needle or ligature carrier. The procedure is then repeated on the opposite side.
There are other embodiments of the sling that may be used to support a urethra or other organ or tissue within a body. The embodiments discussed so far have focused on flat, relatively planar slings. It is possible to add a third dimension to the sling in one or more ways. While there may be advantages related to a flat structure, the portion that supports the urethra is actually shaped into a three-dimensional structure when it is curved under the patient's urethra. Such a three-dimensional structure may be pre-manufactured into sling devices, or sling devices may be adapted individually to suit the needs of a particular patient. The ends of the sling, whether with serrated edges or plain, may be given a third dimension by adding another plane of submucosal tissue cross-wise, as shown in
In
The embodiments of
The primary use of the slings discussed so far has been to support the urethra of the patient. The slings are not limited to supporting the urethra, and may be used for other purposes. For instance, by widening the support portion of the sling, it may be used to support at least a portion of a bladder as well as a urethra. A sling for this purpose is depicted in
Success in the implantation of a sling may produce a result in which the urethra is supported and the user is enabled to control the flow of urine in a natural manner. The desired result of a sling implanted in patient 210 is shown in
The transition segments have focused on narrowing transitions. It is also possible to provide the desired relief by transition segments in which material is perforated, sliced or otherwise weakened in specific areas to provide relief. The relief may be provided by material that has openings sliced into it, holes or windows provided, and the like.
Other embodiments of a relief are shown in
The sling may be made from any suitable material. Suitable collagenous materials include, but are not limited to, purified or reconstituted collagen; bovine or other mammalian pericardium; decellularized dermis; submucosa tissue such as urinary bladder submucosa, stomach submucosa, small intestine submucosa, and uterine submucosa; serosa tissue such as bovine serosa; basement membrane tissue such as liver basement membrane; autologous, allogenic or xenogenic fascia lata; and so on. Materials which constitute a collagen-based extracellular matrix (ECM) are preferred. In general, mammalian tela submucosa tissues, which are collagen based and thus predominantly collagen, are preferred ECM materials. These tissues may be procured from the alimentary, respiratory, urinary or genital tracts of animals.
ECM materials, when used, may optionally retain growth factors or other bioactive components native to the source tissue. For example, the submucosa tissue may include one or more growth factors such as basic fibroblast growth factor (FGF-2), transforming growth factor beta (TGF-beta), epidermal growth factor (EGF), and/or platelet derived growth factor (PDGF). As well, submucosa tissue used in the invention may include other biological materials such as heparin, heparin sulfate, hyaluronic acid, fibronectin and the like.
A preferred material is small intestine submucosa (SIS) obtained from a porcine source, although the material for the sling is not limited to this material. As mentioned above, other materials useful in slings according to the present invention are disclosed in U.S. Pat. No. 6,206,931, hereby incorporated by reference. Cross-linked ECM materials are one embodiment of materials useful in the present invention, as are materials that are not cross-linked. Cross-linked materials tend to be less bioresorbable than non-cross linked materials.
A sling may also be formed from a tissue engineered product involving cell culture techniques, such as the use of stem cell technology or using smooth muscle cells with SIS material. One such technique is to seed smooth muscle cells onto SIS material or other biodegradable scaffold. Other biodegradable scaffolds, some of which are mentioned elsewhere, include polyglycolic acid (PGA), collagen, and extra-cellular matrix materials (ECM), as well as SIS. A sling may also be formed using stem cell technology. One technique is to culture stem cells in a specific medium to induce smooth muscle differentiation. Suitable media include, but are not limited to, SIS, ECM, PGA, and collagen. The new derived cells, formed from Stem cells, could be formed into the product or seeded onto the matrix material to form a sling.
Collagenous materials used for slings may be cross-linked with a chemical cross-linking agent, such as formaldehyde or glutaraldehyde. Other cross-linking agents that may be used include, but are not limited to aldehydes, sulfo-N-hydroxysuccinimide, polyepoxy compounds, and carbodiimides, including 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC). Polyepoxy compounds may include, but are not limited to glycol diglycidyl ether, polyol polyglycidyl ether, and dicarboxylic acid diglycidyl ester. Materials for slings may also be cross-linked by radiation treatment, such as exposure to electron-beam radiation. In some instances, the strength or stiffness may in some ways be degraded by the use of electron-beam radiation. The degree of support or reinforcement necessary may determine the material used. The cross-linking lends additional strength and stiffness to materials, better enabling them to carry loads and absorb stresses. In other applications, non-cross-linked materials may suffice, and their greater flexibility and resilience may serve the patient better than a stronger, stiffer material. In addition, non-crosslinked, more bioresorbable materials are very useful in embodiments of slings useful for implantation within a human body. Slings made from any of these or other materials may also be coated with an antibacterial or an anti-inflammatory treatment to reduce infection or inflammation at the implanted sites. Slings may also be coated with an protease inhibitor to enhance tissue regeneration.
In addition to and potentially in combination with these natural materials, other natural or synthetic materials may be useful as slings or as reinforcements or additions to slings. These materials may include, but are not limited to, nylons, polyesters, polystyrene, polyethylene, polypropylene, polyacrylates, polyvinyl compounds such as polyvinyl chloride, polycarbonates, polytetrafluoroethylene, thermanox, nitrocellulose, cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin, dextran, and the like. In some cases, bioresorbable materials may be indicated. Bioresorbable materials are those which ideally disappear after treatment without leaving a trace of their prior presence. Bioresorbable materials which may be used alone or in conjunction with ECM materials include, but are not limited to, biodegradable polyesters, polyorthoesters, polyglycolide-co-lactides, polyanhydrides, and polyesteramides. The slings for supporting soft tissues within the body may be made by any of these materials, or by a combination of these materials.
In addition to these materials for the slings themselves, a sling for repair of soft tissue in a human body may utilize a protective sheath, as mentioned above. The plastic sheaths desirably protect the sling and help maintain the sling in a sterile condition. In addition, the sheath may be used to help draw the sling through the body. Material for the sheath is preferably a smooth, frictionless plastic, such as polyethylene, but other plastics may also be used for a sheath, including but not limit to, polystyrene and polyvinyl chloride.
Attention has focused on urethral applications for these materials, particularly for female patients. As noted above, slings made from these materials may also be used on male patients, particularly males experiencing urinary disfunction after prostate surgery or other trauma to the urethral region. The slings made from these materials are not limited to supporting the urethra and the bladder, but may also be used for supporting a variety of soft tissues within the body. Slings made from these materials may be used for repair of a rectum or for paravaginal repairs, such as vault prolapse, cystocele, and enterocele. Abdominal walls may use these materials, as well as herniated tissues, prolapsed tissues, and perforated tissues. Suitable applications for herniated tissues may include abdominal, inguinal, diaphragmatic, epigastric, gastroesophegeal, hiatal, intermuscular, mesenteric, paraperitoneal, rectovaginal, uterine and vesical. These materials may also be used for general tissue repair in areas such as an anterior pelvic floor, bladder repair, thoracic walls, and the like.
The sling embodiments of the present invention may be made from one or more of the materials listed above, and may be used for any of the procedures listed herein. The slings are not limited to female urethral support, nor to male urethral support, but may be used in a variety of procedures to support bodily tissues. As mentioned above, multi-layer slings may be fashioned from multiple layers of materials in a variety of techniques in order to strengthen and stiffen the reinforcement.
It will be understood that no limitation of the scope of the invention is intended by the above description and drawings, which is defined by the claims below.
This application claims the benefit of the filing date under 35 U.S.C. §119(e) of Provisional U.S. Patent Application Ser. No. 60/376,575, filed on Apr. 30, 2002, which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3182662 | Shirodkar | May 1965 | A |
3255501 | Laguerre | Jun 1966 | A |
3913179 | Rhee | Oct 1975 | A |
4037603 | Wendorff | Jul 1977 | A |
4477950 | Cisek et al. | Oct 1984 | A |
4509516 | Richmond | Apr 1985 | A |
4696288 | Kuzmak et al. | Sep 1987 | A |
5013292 | Lemay | May 1991 | A |
5032508 | Naughton et al. | Jul 1991 | A |
D319559 | Weiss | Sep 1991 | S |
5112344 | Petros | May 1992 | A |
5250049 | Michael | Oct 1993 | A |
5256133 | Spitz | Oct 1993 | A |
5281237 | Gimpelson | Jan 1994 | A |
5281422 | Badylak et al. | Jan 1994 | A |
5328077 | Lou | Jul 1994 | A |
5337736 | Reddy | Aug 1994 | A |
5362294 | Seitzinger | Nov 1994 | A |
5383904 | Totakura et al. | Jan 1995 | A |
5571117 | Ahn | Nov 1996 | A |
5645568 | Chervitz et al. | Jul 1997 | A |
5647836 | Blake, III et al. | Jul 1997 | A |
5711969 | Patel et al. | Jan 1998 | A |
5746763 | Benderev et al. | May 1998 | A |
5755728 | Maki | May 1998 | A |
5785640 | Kresch et al. | Jul 1998 | A |
5836314 | Benderev et al. | Nov 1998 | A |
5840011 | Landgrebe et al. | Nov 1998 | A |
5842478 | Benderev et al. | Dec 1998 | A |
5873904 | Ragheb et al. | Feb 1999 | A |
5885619 | Patel et al. | Mar 1999 | A |
5899909 | Claren et al. | May 1999 | A |
5934283 | Willem et al. | Aug 1999 | A |
5955110 | Patel et al. | Sep 1999 | A |
5997554 | Thompson | Dec 1999 | A |
5997575 | Whitson et al. | Dec 1999 | A |
6001104 | Benderev et al. | Dec 1999 | A |
6030393 | Corlew | Feb 2000 | A |
6039686 | Kovac | Mar 2000 | A |
6042534 | Gellman et al. | Mar 2000 | A |
6042536 | Tihon et al. | Mar 2000 | A |
6050937 | Benderev | Apr 2000 | A |
6053935 | Brenneman et al. | Apr 2000 | A |
6056688 | Benderev et al. | May 2000 | A |
6068591 | Bruckner et al. | May 2000 | A |
6073315 | Rasmussen | Jun 2000 | A |
6096041 | Gellman et al. | Aug 2000 | A |
6096070 | Ragheb et al. | Aug 2000 | A |
6099547 | Gellman et al. | Aug 2000 | A |
6110101 | Tihon et al. | Aug 2000 | A |
6179840 | Bowman | Jan 2001 | B1 |
6200336 | Pavenik et al. | Mar 2001 | B1 |
6206931 | Cook et al. | Mar 2001 | B1 |
6221005 | Bruckner et al. | Apr 2001 | B1 |
6245082 | Gellman et al. | Jun 2001 | B1 |
6264676 | Gellman et al. | Jul 2001 | B1 |
6273852 | Lehe et al. | Aug 2001 | B1 |
6292700 | Morrison et al. | Sep 2001 | B1 |
6299604 | Ragheb et al. | Oct 2001 | B1 |
6302840 | Benderev | Oct 2001 | B1 |
6319272 | Brenneman et al. | Nov 2001 | B1 |
6322492 | Kovac | Nov 2001 | B1 |
D451372 | Cedarberg, III | Dec 2001 | S |
6328686 | Kovac | Dec 2001 | B1 |
6334446 | Beyar | Jan 2002 | B1 |
6358284 | Fearnot et al. | Mar 2002 | B1 |
6475139 | Miller | Nov 2002 | B1 |
6508833 | Pavenik et al. | Jan 2003 | B2 |
6530951 | Bates et al. | Mar 2003 | B1 |
6575984 | Beyar | Jun 2003 | B2 |
6575998 | Beyar | Jun 2003 | B2 |
6592610 | Beyar | Jul 2003 | B2 |
6595911 | LoVuolo | Jul 2003 | B2 |
6599275 | Fischer, Jr. | Jul 2003 | B1 |
6612977 | Staskin et al. | Sep 2003 | B2 |
6638209 | Landgrebe | Oct 2003 | B2 |
6638210 | Berger | Oct 2003 | B2 |
6641524 | Kovac | Nov 2003 | B2 |
6652450 | Neisz et al. | Nov 2003 | B2 |
6666892 | Hiles et al. | Dec 2003 | B2 |
6676674 | Dudai | Jan 2004 | B1 |
6730064 | Ragheb et al. | May 2004 | B2 |
6774278 | Ragheb et al. | Aug 2004 | B1 |
6936052 | Gellman et al. | Aug 2005 | B2 |
7160333 | Plouhar et al. | Jan 2007 | B2 |
20010018549 | Scetbon | Aug 2001 | A1 |
20010049467 | Lehe et al. | Dec 2001 | A1 |
20010053916 | Rioux | Dec 2001 | A1 |
20020155096 | Chancellor et al. | Oct 2002 | A1 |
20060058578 | Browning | Mar 2006 | A1 |
Number | Date | Country |
---|---|---|
0 248 544 | Apr 1991 | EP |
0 470 308 | Feb 1992 | EP |
0 714 271 | May 1998 | EP |
0 598 976 | Jul 2000 | EP |
1 093 758 | Apr 2001 | EP |
1 151 722 | Nov 2001 | EP |
1 159 921 | Dec 2001 | EP |
0 854 691 | Jan 2002 | EP |
1 159 921 | Jan 2002 | EP |
0 774 240 | Mar 2003 | EP |
WO 9003766 | Apr 1990 | WO |
WO 9700047 | Jan 1997 | WO |
WO 9713465 | Apr 1997 | WO |
WO 9812971 | Apr 1998 | WO |
WO 9819606 | May 1998 | WO |
WO 9835606 | Aug 1998 | WO |
WO 9835632 | Aug 1998 | WO |
WO 9835606 | Dec 1998 | WO |
WO 0009039 | Feb 2000 | WO |
WO 0066030 | Nov 2000 | WO |
WO 0074613 | Dec 2000 | WO |
WO 0117469 | Mar 2001 | WO |
WO 0126588 | Apr 2001 | WO |
WO 0145588 | Jun 2001 | WO |
WO 0145589 | Jun 2001 | WO |
WO 0147574 | Jul 2001 | WO |
WO 0152750 | Jul 2001 | WO |
WO 0156500 | Aug 2001 | WO |
WO 0193656 | Dec 2001 | WO |
WO 0219945 | Mar 2002 | WO |
WO 0226108 | Apr 2002 | WO |
WO 0228315 | Apr 2002 | WO |
WO 02058563 | Aug 2002 | WO |
WO 02065922 | Aug 2002 | WO |
WO 03020168 | Mar 2003 | WO |
WO 03028584 | Apr 2003 | WO |
WO 03030778 | Apr 2003 | WO |
WO 03034891 | May 2003 | WO |
Number | Date | Country | |
---|---|---|---|
20040006353 A1 | Jan 2004 | US |
Number | Date | Country | |
---|---|---|---|
60376575 | Apr 2002 | US |